FrancophonIA/ELRC3.0 huggingface dataset:
English: • if your bowels are, or may be, blocked (obstructed) or you have been warned that your bowels are at risk of becoming blocked.
Slovenian: • če imate ali bi lahko imeli zaporo (obstrukcijo) črevesa ali če so vas opozorili, da se vam lahko pojavi zapora črevesa;
English: Plasma protein binding of naloxegol in humans was low and the fraction unbound ranged from 80% to
Slovenian: Vezava naloksegola na beljakovine v plazmi je pri človeku majhna in nevezani delež sega od 80 do 100 %.
English: • If you miss a dose of Moventig, take it as soon as you remember.
Slovenian: Če ste pozabili vzeti zdravilo Moventig • Če izpustite odmerek zdravila Moventig, ga vzemite, čim se spomnite.
English: It is important to flush the nasogastric tube through with water after administration of the mixture.
Slovenian: Pomembno je, da nazogastrično sondo po dajanju mešanice sperete z vodo.
English: If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.
Slovenian: Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete to zdravilo.
English: A double-blind, randomized, 2-part, crossover, single centre study was conducted to evaluate the effect of quinidine on the pharmacokinetics of naloxegol and the effect of the co-administration of naloxegol and quinidine on morphine-induced miosis in healthy volunteers.
Slovenian: Izvedli so dvojno slepo, randomizirano, 2-delno navzkrižno študijo v enem centru za oceno vpliva kinidina na farmakokinetiko naloksegola ter vpliva sočasne uporabe naloksegola in kinidina na morfinsko povzročeno miozo pri zdravih prostovoljcih.
English: Due to poorer permeability and increased efflux of naloxegol across the blood-brain barrier, related to P-gp substrate properties, the CNS penetration of naloxegol is minimal.
Slovenian: Zaradi slabše permeabilnosti in večjega iztoka naloksegola preko krvno-možganske pregrade, kar je povezano z lastnostmi substrata P-gp, naloksegol le minimalno prodre v osrednje živčevje.
English: You may need to stop taking Moventig
Slovenian: Morda boste morali nehati jemati zdravilo Moventig,
English: • To make sure there is no medicine left, rinse the empty glass with another half a glass of water (120 ml), and drink it
Slovenian: • Da boste zagotovo zaužili celoten odmerek zdravila, prazni kozarec splaknite z dodatnega pol kozarca vode (120 ml) in to vodo popijte.
English: Cancer-related pain
Slovenian: Z rakom povezane bolečine
English: Naloxegol as a crushed tablet mixed in water, given orally or administered through a nasogastric tube into the stomach, is bioequivalent to the whole tablet, with a median tmax of 0.75 and 1.50 hours (range 0.23 to 5.02 hours) for the crushed tablet given orally and the crushed tablet given via NG tube, respectively.
Slovenian: Naloksegol v obliki zdrobljene tablete, zmešane z vodo, uporabljen peroralno ali po nazogastrični sondi v želodec, je biološko enakovreden celi tableti: mediani tmax za peroralno uporabljeno zdrobljeno tableto je 0,75 ure in za zdrobljeno tableto, uporabljeno po nazogastrični sondi, 1,50 ure (razpon: od
English: Skin and subcutaneous tissue disorders
Slovenian: Bolezni kože in podkožja hiperhidroza
English: In a pooled analysis of Kodiac 4 and Kodiac 5 (90, 88 and 99 patients in the placebo, 12.5 mg and 25 mg groups respectively), higher response rates in this population was observed for the 25 mg dose group compared with placebo (p=0.040).
Slovenian: V kumulativni analizi Kodiac 4 in Kodiac 5 (90 bolnikov v skupini s placebom, 88 z 12,5 mg in 99 s 25 mg) so v tej populaciji ugotovili večji delež odziva z odmerkom 25 mg kot s placebom (p = 0,040).
English: Results from a QWBA (Quantitative Whole Body Autoradiography) study in the rat and the lack of antagonism of CNS opiate effects in humans at naloxegol doses less than 250 mg, indicate minimal distribution of naloxegol into the CNS.
Slovenian: (Quantitative Whole Body Autoradiography) pri podganah in odsotnost antagoniziranja opiatnih učinkov v osrednjem živčevju pri človeku ob odmerkih naloksegola manj kot 250 mg kažejo na minimalno porazdelitev naloksegola v osrednje živčevje.
English: Paediatric population The use of naloxegol in the paediatric population has not been studied.
Slovenian: Pediatrična populacija Uporaba naloksegola pri pediatrični populaciji ni raziskana.
English: Tabulated list of adverse reactions Adverse reactions are classified according to frequency and System Organ Class.
Slovenian: Neželeni učinki so razvrščeni po pogostnosti in organskem sistemu.
English: In vitro studies demonstrate that naloxegol is a full neutral antagonist at the mu-opioid receptor.
Slovenian: Študije in vitro kažejo, da je naloksegol polni nevtralni antagonist na mi-opioidnih receptorjih.
English: Safety and tolerability over an extended 12-week period Kodiac 7 was a 12-week safety extension that allowed for patients from Kodiac 4 to continue the same blinded treatment from Kodiac 4 for an additional 12 weeks (placebo, naloxegol 12.5 mg or 25 mg daily).
Slovenian: Študija Kodiac 7 je bila 12-tedensko varnostno podaljšanje, ki je bolnikom v Kodiac 4 omogočilo nadaljevanje istega slepljenega zdravljenja, kot so ga prejemali v Kodiac 4, še dodatnih 12 tednov (placebo, naloksegol 12,5 mg ali 25 mg enkrat na dan).
English: • passing wind
Slovenian: • vetrovi
English: Opioid withdrawal syndrome is a cluster of three or more of the following signs or symptoms: dysphoric mood, nausea, vomiting, muscle aches, lacrimation, rhinorrhoea, pupillary dilation,
Slovenian: Sindrom odtegnitve opioidov je skupek treh ali več izmed naslednjih znakov ali simptomov: disforično razpoloženje, navzea ali bruhanje, mišične bolečine, solzenje ali rinoreja, razširjenost zenice ali piloerekcija ali znojenje, driska, zehanje, zvišana telesna temperatura ali nespečnost.
English: Concurrent methadone use
Slovenian: Sočasna uporaba metadona
English: There is a theoretical possibility that naloxegol could provoke opioid withdrawal in a breast-fed neonate whose mother is taking an opioid receptor agonist.
Slovenian: Obstaja teoretična možnost, da bi naloksegol povzročil odtegnitev opioidov pri dojenem novorojenčku, čigar mati jemlje agonist opioidnih receptorjev.
English: Posology The recommended dose of Moventig is 25 mg once daily.
Slovenian: Priporočeni odmerek zdravila Moventig je 25 mg enkrat na dan.
English: In Kodiac 5 the corresponding times to first post dose SBM were 38.2, 12.8, and 18.1 hours, respectively.
Slovenian: V Kodiac 5 so bili ustrezni časi do prvega spontanega iztrebljanja po odmerku 38,2, 12,8 in 18,1 ure.
English: Other possible side effects: Very common (may affect more than 1 in 10 people):
Slovenian: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov):
English: Therefore, concomitant use with strong CYP3A4 inhibitors is contraindicated (see section 4.3).
Slovenian: Zato je sočasna uporaba močnih zaviralcev CYP3A4 kontraindicirana (glejte poglavje 4.3).
English: Patients taking methadone as primary therapy for their pain condition were observed in clinical trials to have a higher frequency of gastrointestinal adverse reactions (such as abdominal pain and diarrhoea) than patients not receiving methadone.
Slovenian: V kliničnih preskušanjih so opažali, da imajo bolniki, ki za primarno zdravljenje bolečinskega stanja jemljejo metadon, pogosteje neželene učinke na prebavilih (npr. bolečine v trebuhu in drisko) kot bolniki, ki ne dobivajo metadona.
English: Tablet core mannitol (E421) cellulose microcrystalline (E460) croscarmellose sodium (E468) magnesium stearate (E470b) propyl gallate (E310)
Slovenian: Jedro tablete manitol (E421) mikrokristalna celuloza (E460) premreženi natrijev karmelozat (E468) magnezijev stearat (E470b) propilgalat (E310)
English: There is a theoretical potential for provoking opioid withdrawal in the foetus with use of an opioid receptor antagonist in the mother, who is being treated with a concurrent opioid.
Slovenian: Obstaja teoretična možnost za sprožitev odtegnitve opioidov pri plodu, če je antagonist opioidnih receptorjev uporabljen pri materi, ki je sočasno prejemala tudi opioid.
English: Very Common Common Uncommon Rare
Slovenian: Neznana pogostnost
English: Naloxegol must not be used in patients with known or suspected gastrointestinal obstruction or in patients at increased risk of recurrent obstruction, or in patients with underlying cancer who are at heightened risk of GI perforation (see section 4.3).
Slovenian: Naloksegola ne smete dajati bolnikom z znano ali domnevno obstrukcijo prebavil, niti bolnikom s povečanim tveganjem za ponovno obstrukcijo, niti bolnikom z rakom, pri katerih je tveganje za perforacijo prebavil zvečano (glejte poglavje 4.3).
English: Patients who had a QTcF >500 msec at screening, had a recent history of myocardial infarction within 6 months before randomization, had symptomatic congestive heart failure, or had any other overt CV disease were excluded from the clinical studies.
Slovenian: V klinične študije niso bili vključeni bolniki, ki so imeli ob presejanju QTcF > 500 msec, ali so imeli v anamnezi miokardni infarkt v 6 mesecih pred randomizacijo, so imeli kongestivno srčno popuščanje ali kakšno drugo manifestno kardiovaskularno bolezen.
English: If side effects impacting tolerability occur, naloxegol should be discontinued.
Slovenian: Če se pojavijo neželeni učinki, ki vplivajo na prenašanje, je treba z uporabo naloksegola prenehati.
English: In the pooled data from clinical trials the most commonly reported adverse reactions with naloxegol (≥ 5%) are: abdominal pain, diarrhoea, nausea, headache and flatulence.
Slovenian: V zbranih podatkih kliničnih preskušanj so bili najpogosteje poročani neželeni učinki naloksegola (≥ 5 %) bolečine v trebuhu, driska, navzea, glavobol in flatulenca.
English: The use of naloxegol is not recommended in such patients.
Slovenian: Uporaba naloksegola pri takšnih bolnikih ni priporočljiva.
English: Stop taking the medicine and tell your doctor straight away if you develop opioid withdrawal symptoms (if you have a combination of three or more of these symptoms: feeling depressed, nausea, vomiting, muscle aches, increased tearing, runny nose, dilation of the pupils, goosebumps, excess sweating, diarrhoea, yawning, fever or insomnia) which would usually occur within the first few days after starting naloxegol.
Slovenian: Prenehajte jemati zdravilo in nemudoma povejte zdravniku, če se pri vas razvijejo simptomi odtegnitve opioidov (če imate kombinacijo treh ali več od naslednjih simptomov: občutek potrtosti, slabost v želodcu, bruhanje, bolečine v mišicah, močnejše solzenje, izcedek iz nosu, razširjene zenice,
English: No data are available on the concomitant use of naloxegol with grapefruit juice.
Slovenian: O sočasni uporabi naloksegola z grenivkinim sokom ni podatkov.
English: Co-administration of the P-gp inhibitor quinidine resulted in a 1.4 fold increase in the AUC (90% CI: 1.3-1.5) and a 2.4 fold increase in the Cmax (90% CI: 2.2-2.8) of naloxegol.
Slovenian: Sočasna uporaba zaviralca P-gp, kinidina, je povzročila 1,4-kratno (90 % IZ: 1,3-1,5) zvišanje AUC naloksegola in 2,4-kratno (90 % IZ: 2,2-2,8)
English: If you take more Moventig than you should, talk to a doctor or go to hospital.
Slovenian: Če ste vzeli večji odmerek zdravila Moventig, kot bi smeli Če ste vzeli večji odmerek zdravila Moventig, kot bi smeli, se posvetujte z zdravnikom ali pojdite v bolnišnico.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and fertility.
Slovenian: Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti in plodnosti ne kažejo posebnega tveganja za človeka.
English: • if you have stomach ulcers, Crohn's Disease (an illness where your gut is inflamed), diverticulitis (another illness where your gut is inflamed), cancer in your gut or ‘peritoneum' (the lining of your stomach area), or any conditon that might damage the wall of your bowel
Slovenian: • če imate razjede na želodcu, Crohnovo bolezen (bolezen, ki povzroči vnetje črevesa), divertikulitis (druga bolezen, pri kateri se pojavi vnetje črevesa), raka na črevesu ali potrebušnici (to je mrena, ki prekriva trebušne organe) ali kakršno koli bolezen ali motnjo, ki lahko poškoduje steno črevesa, • če imate trenutno nenavadno hude, dolgotrajne bolečine v trebuhu ali se vam takšne bolečine poslabšajo,
English: There was no relevant impact on abdominal symptoms in either study (p=0.256 and p=0.916, Kodiac 4 and 5, respectively).
Slovenian: Niti v eni niti v drugi študiji ni bilo pomembnega vpliva na trebušne simptome (Kodiac 4 p = 0,256 in Kodiac 5 p = 0,916).
English: There was a higher incidence of discontinuations in patients taking the 25 mg dose compared to placebo due to diarrhoea (0.7% for placebo versus 3.1% for naloxegol 25 mg) and abdominal pain (0.2% versus 2.9%, respectively).
Slovenian: Incidenca prekinitev zdravljenja je bila pri bolnikih, ki so dobivali odmerek 25 mg, večja kot med prejemniki placeba, in sicer tako zaradi driske (0,7 % za placebo in 3,1 % za 25 mg naloksegola) kot zaradi bolečin v trebuhu (0,2 % za placebo in 2,9 % za 25 mg naloksegola).
English: Thus renal excretion is a minor clearance pathway for naloxegol.
Slovenian: Izločanje skozi ledvice je tako manj pomembna pot očistka naloksegola.
English: Therefore, Moventig is not recommended in patients who are taking strong CYP3A4 inducers (see section 4.4).
Slovenian: Zato zdravilo Moventig ni priporočljivo za bolnike, ki jemljejo močne induktorje CYP3A4 (glejte poglavje 4.4).
English: Pregnancy There are limited data from the use of naloxegol in pregnant women.
Slovenian: Podatkov o uporabi naloksegola pri nosečnicah je malo.
English: Clinical studies of naloxegol did not include sufficient numbers of patients aged 75 years or over to determine whether they respond differently than younger patients, however, based on the mode of action of the active substance there are no theoretical reasons for any requirement for dose adjustments in this age group.
Slovenian: Klinične študije naloksegola niso vključile dovolj bolnikov v starosti 75 let in več, da bi bilo mogoče ugotoviti, ali se starejše osebe odzivajo drugače kot mlajše.
English: Long-term exposure to naloxegol 25 mg, up to 52 weeks, was generally safe and well tolerated in the treatment of OIC patients with non-cancer-related pain.
Slovenian: Med dolgotrajno izpostavljenostjo 25 mg naloksegola do 52 tednov je bilo zdravilo pri bolnikih z OIC in bolečinami, nepovezanimi z rakom, na splošno varno in so ga dobro prenašali.
English: In this study, naloxegol at doses of 12.5 mg and 25 mg was generally safe and well tolerated as compared with placebo in the treatment of OIC patients with non-cancer-related pain.
Slovenian: V tej študiji je bil naloksegol v odmerkih 12,5 mg in 25 mg v primerjavi s placebom pri bolnikih z OIC in bolečinami, nepovezanimi z rakom, na splošno varen in so ga dobro prenašali.
English: For definition of inadequate response to laxative(s), see section 5.1.
Slovenian: Za opredelitev nezadostnega odziva na odvajala glejte poglavje 5.1.
English: Patients with mean Numeric Rating Scale (NRS) pain scores equal to or higher than 7 were not studied due to the risk of confounding the efficacy result as a result of uncontrolled pain.
Slovenian: Preučili niso bolnikov s povprečno oceno bolečin na NRS (Numeric Rating Scale) ≥ 7, in sicer zaradi tveganja, da bi nenadzorovane bolečine moteče vplivale na rezultat učinkovitosti.
English: • nausea (feeling sick to the stomach)
Slovenian: • slabost v želodcu (siljenje na bruhanje)
English: Doses of naloxegol up to 1,000 mg were administered in healthy volunteers in clinical studies.
Slovenian: V kliničnih študijah so zdravi prostovoljci dobili odmerke naloksegola do 1.000 mg.
English: To qualify as LIR, in the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre study period.
Slovenian: Opredelitev nezadostnega odziva na odvajala (LIR - laxative inadequate responder) Med bolnike z nezadostnim odzivom na odvajala so se uvrstili tisti, ki so imeli v dveh tednih pred prvim obiskom v študiji sočasne in vsaj zmerno hude simptome OIC ter so uporabljali vsaj eno skupino odvajal najmanj štiri dni med obdobjem pred študijo.
English: Patients with known or suspected gastrointestinal (GI) obstruction or in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation (see section 4.4).
Slovenian: Bolniki z znano obstrukcijo prebavil ali sumom nanjo, ali bolniki z večjim tveganjem za ponovno obstrukcijo, ker obstaja možnost perforacije prebavil (glejte poglavje 4.4).
English: 10 film-coated tablets 30 film-coated tablets 90 film-coated tablets 10 x 1 film-coated tablets 30 x 1 film-coated tablets 90 x 1 film-coated tablets 100 x 1 film-coated tablets
Slovenian: 10 filmsko obloženih tablet 30 filmsko obloženih tablet 90 filmsko obloženih tablet 10 x 1 filmsko obložena tableta 30 x 1 filmsko obložena tableta 90 x 1 filmsko obložena tableta 100 x 1 filmsko obložena tableta
English: Consideration may be given to lowering the dose to 12.5mg in patients experiencing severe gastrointestinal adverse events depending upon the response and tolerability of individual patients.
Slovenian: Pri bolnikih s hudimi neželenimi učinki na prebavilih pride v poštev zmanjšanje odmerka na 12,5 mg, odvisno od odziva in prenašanja pri posameznem bolniku.
English: Contents of the pack and other information
Slovenian: Shranjevanje zdravila Moventig Vsebina pakiranja in dodatne informacije
English: Moventig 12.5 mg: a mauve coloured, oval, dimensions 10.5 x 5.5 mm film-coated tablet, marked “nGL” on one side and “12.5” on the other side.
Slovenian: Moventig 12,5 mg: 10,5 x 5,5 mm velike filmsko obložene tablete ovalne oblike in svetlo vijoličaste barve z oznako »nGL« na eni strani in »12,5« na drugi strani.
English: Naloxegol at therapeutic doses has minimal uptake across the blood brain barrier.
Slovenian: Naloksegol v terapevtskih odmerkih le minimalno prehaja skozi krvno-možgansko pregrado.
English: In a few cases, symptoms suggestive of opioid withdrawal when taking naloxegol 25 mg were observed in patients taking methadone for their pain condition.
Slovenian: V posameznih primerih so pri bolnikih, ki so za zdravljenje bolečinskega stanja jemali metadon, med uporabo 25 mg naloksegola opažali simptome, ki nakazujejo na odtegnitev opioidov.
English: OIC was confirmed through a two week run in period and defined as < 3 spontaneous bowel movements (SBMs) per week on average with constipation symptoms associated with at least 25% of bowel movements.
Slovenian: morfinskih ekvivalentnih enot opioidov in so imeli po lastni navedbi OIC. OIC je bila potrjena med dvotedenskim obdobjem uvajanja in je bila opredeljena kot povprečno < 3 spontana iztrebljanja na teden hkrati s simptomi zaprtja pri vsaj 25 % iztrebljanj.
English: 30 film-coated tablets 90 film-coated tablets 30 x 1 film-coated tablets 90 x 1 film-coated tablets
Slovenian: 30 filmsko obloženih tablet 90 filmsko obloženih tablet 30 x 1 filmsko obložena tableta 90 x 1 filmsko obložena tableta
English: Pack sizes of 10 x 1, 30 x 1, 90 x 1 and 100 x 1 film-coated tablets in perforated unit dose blisters.
Slovenian: Pakiranje z 10 x 1, 30 x 1, 90 x 1 in 100 x 1 filmsko obloženo tableto v perforiranih pretisnih omotih za posamezni odmerek.
English: Patients with moderate or severe hepatic insufficiency (Child's-Pugh Class B or C) were excluded from the Phase III studies (Kodiac 4 and 5).
Slovenian: Študiji III. faze (Kodiac 4 in 5) nista vključili bolnikov z zmerno ali hudo okvaro jeter (Child-Pugh razred B ali C).
English: The starting dose for patients taking moderate CYP3A4 inhibitors is 12.5 mg once daily and the dose can be increased to 25 mg if 12.5 mg is well tolerated by the patient (see section 4.2).
Slovenian: Začetni odmerek za bolnike, ki jemljejo zmerne zaviralce CYP3A4 (npr. diltiazem, verapamil), je 12,5 mg enkrat na dan. Odmerek je mogoče povečati na 25 mg, če bolnik dobro prenaša odmerek
English: Moventig 12.5 mg tablets are available in aluminium blisters in pack sizes of 30 or 90 film-coated tablets in non-perforated blisters and 30x 1 or 90x1 film-coated tablets in perforated unit dose blisters.
Slovenian: Zdravilo Moventig 12,5 mg tablete je na voljo v aluminijskih pretisnih omotih v pakiranjih s 30 ali 90 filmsko obloženimi tabletami v neperforiranih pretisnih omotih ter kot 30 x 1 ali 90 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za posamezni odmerek.
English: Efficacy in the patient population targeted in this SmPC Response over 12 weeks in the LIR group
Slovenian: Odziv v 12 tednih v skupini z LIR
English: EU/1/14/962/001 30 film-coated tablets EU/1/14/962/002 90 film-coated tablets EU/1/14/962/008 30 x 1 film-coated tablets (unit dose) EU/1/14/962/003 90 x 1 film-coated tablets (unit dose)
Slovenian: EU/1/14/962/001 30 filmsko obloženih tablet EU/1/14/962/002 90 filmsko obloženih tablet EU/1/14/962/008 30 x 1 filmsko obložena tableta EU/1/14/962/003 90 x 1 filmsko obložena tableta
English: Do not take Moventig if any of the above apply to you.
Slovenian: Ne vzemite zdravila Moventig, če kaj od naštetega velja za vas.
English: Moventig 25 mg: a mauve coloured, oval, dimensions 13 x 7 mm, film-coated tablet, marked “nGL” on one side and “25” on the other side.
Slovenian: Moventig 25 mg: 13 x 7 mm velike filmsko obložene tablete ovalne oblike in svetlo vijoličaste barve z oznako »nGL« na eni strani in »25« na drugi strani.
English: The Cmax and area under the plasma concentration-time curve (AUC) were increased by approximately 30% and 45%, respectively.
Slovenian: Cmax se je zvišala za približno 30 %, površina pod krivuljo plazemske koncentracije po času (AUC) pa za približno
English: Moventig 25 mg tablets are available in aluminium blisters in pack sizes of 10, 30 or 90 film--coated tablets in non-perforated blisters and 10x1, 30x1, 90x1 or 100x1 film-coated tablets in perforated unit dose blisters.
Slovenian: Zdravilo Moventig 25 mg tablete je na voljo v aluminijskih pretisnih omotih v pakiranjih z 10, 30 ali 90 filmsko obloženimi tabletami v neperforiranih pretisnih omotih ter kot 10 x 1, 30 x 1, 90 x 1 ali 100 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za posamezni odmerek.
English: Naloxegol use is therefore not recommended during pregnancy.
Slovenian: Zato uporaba naloksegola med nosečnostjo ni priporočljiva.
English: If opioid withdrawal syndrome is suspected the patient should discontinue Moventig and contact their physician.
Slovenian: V primeru suma na sindrom odtegnitve opioidov mora bolnik prenehati jemati zdravilo Moventig in se posvetovati z zdravnikom.
English: Clinically important disruptions of the blood-brain barrier Naloxegol is a peripherally acting mu-opioid receptor antagonist with restricted access to the central nervous system (CNS).
Slovenian: Naloksegol je periferno delujoč antagonist mi-opioidnih receptorjev z omejenim dostopom v osrednje živčevje (CNS - Central Nervous System).
English: It is unknown whether naloxegol is excreted in human milk.
Slovenian: Ni znano, ali se naloksegol pri človeku izloča v materino mleko.
English: Enterohepatic recirculation may be an explanation as extensive biliary excretion was seen in the rat.
Slovenian: Pojasnilo za to je lahko enterohepatično kroženje, kajti pri podganah so ugotovili obsežno izločanje z žolčem.